Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors

NCT03348514 | Completed Phase 1 Results FDA Drug

• 1 other identifier: CPX-POM-01-001
• Study Type: interventional
• Target: 19
• Locations: 1 country
• Sites: 5

Brief Summary

This is a first-in-human, Phase I, multicenter, open label, dose escalation study to evaluate the DLTs and MTD and to determine the recommended Phase 2 dose (RP2D) of CPX-POM administered IV in patients with any histologically- or cytologically-confirmed solid tumor type.

Conditions

Advanced Solid Tumors

Outcome Measures

Primary Outcomes (2)

• Number of Participants With Dose Limiting Toxicities (DLTs) of CPX-POM

  The primary objective of this study is to evaluate the dose limiting toxicities (DLTs) of ciclopirox phosphoryloxymethyl ester (CPX-POM) administered intravenously (IV) and establish the CPX POM dose recommended for further investigation. A DLT will include some Grade 3 or 4 AEs (as assessed by CTCAE version 4.03) if deemed related to study drug. In addition, any patient who is unable to receive 80% of the expected dose of CPX-POM (i.e., patients who are unable to receive at least 4 of the 5 scheduled doses) because of AEs will be considered to have a DLT. In order to identify any DLTs, safety assessments including AEs, physical examinations, vital signs, and clinical laboratory tests will be conducted during each study visit through Day 22.

  Up to 22 days for each cohort

• Determine the Maximum Tolerated Dose (MTD) of CPX-POM

  The primary objective of this study is to evaluate the maximum tolerated dose (MTD) of ciclopirox phosphoryloxymethyl ester (CPX-POM) administered intravenously (IV) and establish the CPX POM dose recommended for further investigation. MTD was determined by testing increasing doses up to 1200 mg/m\^2 by IV. The MTD is defined as the dose BELOW that dose which causes DLTs in ≥33% of patients.

  Days 1, 2, 3, 4, 5, 6, 10, 22 and 28

Secondary Outcomes (8)

• Assess Plasma PK: Cmax (ng/mL) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.

  Days 5-6

• Assess Plasma PK: Terminal Half-life of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.

  Days 5-6

• Assess Plasma PK: AUCss (ng/mL/hr) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.

  Days 5-6

• Assess Plasma PK: Cls (mL/hr/kg) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.

  Days 5-6

• Assess Plasma PK: Vd and Vss (mL/kg) of the Active Metabolite, Ciclopirox (CPX), Following Five Consecutive Days of Once Daily Dosing.

  Days 5-6

Study Arms (8)

CPX-POM - 30 mg/m^2

EXPERIMENTAL

Drug: CPX-POM - 30 mg/m^2

CPX-POM - 60 mg/m^2

EXPERIMENTAL

Drug: CPX-POM - 60 mg/m^2

CPX-POM - 120 mg/m^2

EXPERIMENTAL

Drug: CPX-POM - 120 mg/m^2

CPX-POM - 240 mg/m^2

EXPERIMENTAL

Drug: CPX-POM - 240 mg/m^2

CPX-POM - 360 mg/m^2

EXPERIMENTAL

Drug: CPX-POM - 360 mg/m^2

CPX-POM - 600 mg/m^2

EXPERIMENTAL

Drug: CPX-POM - 600 mg/m^2

CPX-POM - 900 mg/m^2

EXPERIMENTAL

Drug: CPX-POM - 900 mg/m^2

CPX-POM - 1200 mg/m^2

EXPERIMENTAL

Drug: CPX-POM - 1200 mg/m^2

Interventions

CPX-POM - 30 mg/m^2 DRUG

CPX-POM

CPX-POM - 30 mg/m^2

CPX-POM - 60 mg/m^2 DRUG

CPX-POM

CPX-POM - 60 mg/m^2

CPX-POM - 120 mg/m^2 DRUG

CPX-POM

CPX-POM - 120 mg/m^2

CPX-POM - 240 mg/m^2 DRUG

CPX-POM

CPX-POM - 240 mg/m^2

CPX-POM - 360 mg/m^2 DRUG

CPX-POM

CPX-POM - 360 mg/m^2

CPX-POM - 600 mg/m^2 DRUG

CPX-POM

CPX-POM - 600 mg/m^2

CPX-POM - 900 mg/m^2 DRUG

CPX-POM

CPX-POM - 900 mg/m^2

CPX-POM - 1200 mg/m^2 DRUG

CPX-POM

CPX-POM - 1200 mg/m^2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient is male or female aged ≥18 years.
• Patient provided signed and dated informed consent prior to initiation of any study procedures.
• Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 (fully active, able to carry out all pre-disease activities without restriction) or 1 (unable to perform physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature).
• Patient has a predicted life expectancy of ≥3 months.
• Dose escalation cohorts only: Patient has adequate renal function (creatinine ≤1.5 × the upper limit of normal \[ULN\]) or a glomerular filtration rate (GFR) of ≥50 mL/min/1.73 m\^2). Expansion cohort only: Patient has a GFR of ≥30 mL/min/1.73 m\^2.
• Patient has adequate hepatic function, as evidenced by a total bilirubin ≤1.5 × ULN, aspartate transaminase (AST), and /or alanine transaminase (ALT) ≤3 × ULN or ≤5 ×ULN, if due to liver involvement by tumor.
• Patient has adequate bone marrow function, as evidenced by hemoglobin ≥9.0 g/dL in the absence of transfusion within the previous 72 hours, platelet count ≥100×10\^9cells/L, and absolute neutrophil count (ANC) ≥1.5×10\^9 cells/L.
• Patient has no significant ischemic heart disease or myocardial infarction (MI) within 6 months before the first dose of CPX-POM and currently has adequate cardiac function, as evidenced by a left ventricular ejection fraction of \>50% as assessed by multi-gated acquisition (MUGA) or ultrasound/echocardiography (ECHO); and corrected QT interval (QTc) \<470 msec by Fridericia (QTcF). The eligibility of patients with ventricular pacemakers for whom the QT interval may not be accurately measurable will be determined on a case-by-case basis by the Sponsor in consultation with the Medical Monitor.
• Patient and his/her partner agree to use adequate contraception after providing written informed consent through 3 months after the last dose of CPX-POM, as follows:
• For women: Negative pregnancy test during Screening and at Day 1 of each treatment cycle and compliant with a medically-approved contraceptive regimen during and for 3 months after the treatment period or documented to be surgically sterile or postmenopausal.
• For men: Compliant with a medically-approved contraceptive regimen during and for 3 months after the treatment period or documented to be surgically sterile. Men whose sexual partners are of child-bearing potential must agree to use 2 methods of contraception prior to study entry, during the study, and for 3 months after the treatment period.
• Patient is willing and able to participate in the study and comply with all study requirements.

You may not qualify if:

• Patient has a history of risk factors for torsade de pointes (e.g., heart failure, hypokalemia, family history of long QT syndrome) or requires the use of concomitant medications that prolong the QT/QTc interval during study participation. Patients should not receive anti-emetic medications before and following Dose 1 of Cycle 1 for each treatment cohort. However, anti-emetics such as ondansetron or granisetron that have a mild QTc prolonging effect are allowed starting with Dose 2 of Cycle 1, if used with caution and attention to the approved labelling.
• Patient has an abnormal cardiac appearance/heart size, as evidenced by chest X-ray or computed tomography (CT) scan.
• Patient has an uncontrolled or severe intercurrent medical condition (including uncontrolled brain metastases). Patients with stable brain metastases either treated or being treated with a stable dose of steroids/anticonvulsants, with no dose change within 4 weeks before the first dose of CPX-POM and no anticipated dose change, are allowed. The decision to exclude a patient from the study for an uncontrolled or severe intercurrent medical condition will be made by the Principal Investigator. Examples could include epilepsy, resistant infection, or any other neurological disease that would make clinical assessment difficult.
• Patient underwent major surgery within 4 weeks before the first dose of CPX-POM or received cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy, biologic or immunotherapy, etc.) or an drug or device within 4 weeks (6 weeks for mitomycin C and nitrosoureas) or 5 half-lives of that agent (whichever is shorter) before the first dose of CPX-POM. A minimum of 10 days between termination of the investigational drug and administration of CPX-POM is required. In addition, any drug-related toxicity, with the exception of alopecia, should have recovered to ≤Grade 1.
• If female, patient is pregnant or breast-feeding.
• Patient has evidence of a serious active infection (e.g., infection requiring treatment with intravenous antibiotics).
• Patient has active Hepatitis A infection.
• Patient known human immunodeficiency virus (HIV) or Hepatitis B or C infection, as such patients may be at increased risk for toxicity due to concomitant treatment and disease-related symptoms may preclude accurate assessment of the safety of CPX POM.
• Patient has an important medical illness or abnormal laboratory finding that, in the Investigator's opinion, would increase the risk of participating in this study.
• Patient is taking warfarin.
• Patient has a history of other malignancy treated with curative intent within the previous 5 years with the exception of adequately treated non-melanoma skin cancer or carcinoma in situ of the cervix. Patients with previous invasive cancers are eligible if the treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease.
• Patient has known allergy or hypersensitivity to components of CPX-POM.
• Patient is taking any iron replacement therapy administered IV, IM, or orally due to the potential for loss of anticancer activity due to drug and metabolites chelating iron.

Sponsors & Collaborators

• CicloMed LLC: lead
• Cmed Clinical Services: collaborator

Study Sites (5)

Sarah Cannon Research Institute

Denver, Colorado, 80218, United States

Location

Florida Cancer Specialists & Research Institute

Sarasota, Florida, 34232, United States

Location

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Location

Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States

Location

Tennessee Oncology PLLC

Nashville, Tennessee, 37203, United States

Location

Related Publications (2)

• Weir SJ, Dandawate P, Standing D, Bhattacharyya S, Ramamoorthy P, Rangarajan P, Wood R, Brinker AE, Woolbright BL, Tanol M, Ham T, McCulloch W, Dalton M, Reed GA, Baltezor MJ, Jensen RA, Taylor JA 3rd, Anant S. Fosciclopirox suppresses growth of high-grade urothelial cancer by targeting the gamma-secretase complex. Cell Death Dis. 2021 May 31;12(6):562. doi: 10.1038/s41419-021-03836-z.

  PMID: 34059639 DERIVED

• Weir SJ, Wood R, Schorno K, Brinker AE, Ramamoorthy P, Heppert K, Rajewski L, Tanol M, Ham T, McKenna MJ, McCulloch W, Dalton M, Reed GA, Jensen RA, Baltezor MJ, Anant S, Taylor JA 3rd. Preclinical Pharmacokinetics of Fosciclopirox, a Novel Treatment of Urothelial Cancers, in Rats and Dogs. J Pharmacol Exp Ther. 2019 Aug;370(2):148-159. doi: 10.1124/jpet.119.257972. Epub 2019 May 21.

  PMID: 31113837 DERIVED

Results Point of Contact

• Title: Dr. John A Taylor III
• Organization: University of Kansas Medical Center

Jtaylor27@kumc.edu

913-588-8170

Study Officials

• John A Taylor III, MD, MSc

  University of Kansas Medical Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: This is a Phase I, first-in-human, multicenter, open label, dose escalating study to evaluate the DLTs and MTD and to determine the recommended Phase 2 dose (RP2D) of CPX-POM administered IV in patients with any histologically- or cytologically-confirmed solid tumor type.

Study Record Dates

• First Submitted: November 15, 2017
• First Posted: November 21, 2017
• Study Start: January 15, 2018
• Primary Completion: May 31, 2020
• Study Completion: May 31, 2020
• Last Updated: December 3, 2021
• Results First Posted: November 17, 2021

Record last verified: 2021-12

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP

Locations

US (5)